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Extended-spectrum-β-lactamase (ESBL)/AmpC producing Enterobacteriaceae have been
reported worldwide amongst isolates obtained from humans, food-producing animals,
companion animals, and environmental sources. However, data on prevalence of fecal
carriage of ESBL/AmpC producing Enterobacteriaceae in healthy companion animals is
limited. This pilot study describes the prevalence of ESBL/AmpC encoding genes in
healthy cats and dogs, and cats and dogs with diarrhea. Twenty fecal samples of each
group were cultured on MacConkey agar supplemented with 1 mg/L cefotaxime and in
LB-enrichment broth supplemented with 1 mg/L cefotaxime, which was subsequently
inoculated on MacConkey agar supplemented with 1 mg/L cefotaxime. ESBL/AmpC
genes were identiﬁed using the Check-Points CT103 micro array kit and subsequently by
sequencing analysis. Chromosomal ampC promoter mutations were detected by PCR and
sequencing analysis. From the healthy and diarrheic dogs, respectively 45 and 55% were
positive for Escherichia coli with reduced susceptibility for cefotaxime. From the healthy
and diarrheic cats, the estimated prevalencewas respectively 0 and 25%. One diarrheic cat
was positive for both reduced susceptible E. coli and Proteus mirabilis. The ESBL/AmpC
genes found in this study were mainly blaCTX−M−1, but also blaCTX−M ,−14 blaCTX−M−15,
blaTEM 52 bla−StPaul, SHV bla−12, and− CMY d−2 were detected.This pilot study showe that the
prevalence of ESBL/AmpC producing Enterobacteriaceae in healthy and diarrheic dogs,
and diarrheic cats was relatively high. Furthermore, the genes found were similar to those
found in isolates of both human and food-producing animal origin. However, since the size
of this study was relatively small, extrapolation of the data to the general population of cats
and dogs should be done with great care.
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INTRODUCTION
Extended-spectrum-β-lactamase (ESBL) and plasmid mediated
(p)AmpC-producing Enterobacteriaceae have been isolated from
humans, different animal species, and the environment world-
wide. ESBL/AmpC producing Enterobacteriaceae in both humans
and animals have also been reported increasingly (Coque et al.,
2008; Wieler et al., 2011). One of the main concerns is that resis-
tance caused by these enzymes may result in reduced efﬁcacy of
antimicrobial therapy or therapy failure. Despite many studies on
ESBL/AmpC producing bacteria from different sources, clear data
especially on routes of transmission is still lacking. Therefore the
epidemiology of ESBL/pAmpC’s is poorly understood. One of the
driving forces behind the increased resistance is the use of 3rd and
4th generation cephalosporins in both humans and animals (Dutil
et al., 2010; Damborg et al., 2011, 2012). Resistance to these com-
pounds may appear very quickly in case food-producing animals
receive antimicrobial treatment resulting in a subsequent increase
in resistance in the human population, as was shown in poul-
try and humans (Dutil et al., 2010). A similar increase was also
shown within individual dogs and horses treated with antimicro-
bials (Damborg et al., 2011, 2012). In companion animals, among
others, the 1st generation cephalosporin cephalexin and 3rd gener-
ation, long acting cephalosporin cefovecin are commonly used and
licensed in Europe. Companion animals have also been suggested
as potential reservoir for antimicrobial resistant bacteria (Guard-
abassi et al., 2004). Several studies have reported the presence
of ESBL/pAmpC-producing Enterobacteriaceae in clinical samples
from companion animals (Schink et al., 2011; Dierikx et al., 2012b;
Ewers et al., 2012), however, knowledge about intestinal carriage
of ESBL/AmpC’s in healthy companion animals is limited (Costa
et al., 2008; Murphy et al., 2009; Gandolﬁ-Decristophoris et al.,
2013). In these studies, all using different isolation methods, the
prevalence of Escherichia coli with reduced susceptibility to 3rd
generation cephalosporins in dogs varied from0 to 17%and in cats
from 0 to 12%. The present study combined the analysis of intesti-
nal carriage of Enterobacteriaceae with reduced susceptibility to
cefotaxime in both healthy dogs and cats, and dogs and cats with
diarrhea.
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MATERIALS AND METHODS
SAMPLE COLLECTION
Fecal samples were collected from December 2011 to March 2012
from healthy dogs (n = 20) and cats (n = 20) from different
parts of the Netherlands. The samples from the healthy dogs
were randomly selected from a longitudinal study on the pres-
ence of enteropathogens. Fecal samples from dogs (n = 20) and
cats (n = 20) with diarrhea which were submitted for bacterio-
logical and parasitological examination between December 2011
and February 2012 to the Veterinary Microbiological Diagnos-
tic Center (VMDC) of the Faculty of Veterinary Medicine of
Utrecht University were included. A cotton swab was used to
inoculate each sample both onto MacConkey agar supplemented
with 1 mg/L cefotaxime (MacC+) and in 1 ml LB-medium sup-
plemented with 1 mg/L cefotaxime (LB+) for enrichment. After
overnight incubation 10 μl LB+ was plated on MacC+. From
samples showing growth on MacC+ without previous selective
enrichment, ﬁve colonies were selected. From samples showing
growth on MacC+ after selective enrichment, one colony was
selected.
SPECIES IDENTIFICATION
Species identiﬁcation was performed biochemically on all isolates
that were selected for further analysis using triple sugar iron (TSI)
and ornithine decarboxylase (ODC) and additionally checked for
urease production and tryptophan reduction (indole).
ESBL/AmpC CHARACTERIZATION
To identify ESBL/AmpC producing phenotypes, all selected iso-
lates were screened with a double disk synergy test including
cefotaxime (30 μg), cefotaxime with clavulanic acid (30/10 μg),
ceftazidime (30 μg), ceftazidime with clavulanic acid (30/10 μg)
and cefoxitin (30 μg; Beckton, Dickinson and Company, Breda,
Netherlands). Results were interpreted according to CLSI guide-
lines (CLSI, 2006).
From each animal positive for ESBL/AmpC-producing Enter-
obacteriaceae, one isolate was selected for molecular characteri-
zation. If an animal harbored isolates with different phenotypes,
based on biochemical analysis and disk diffusion, one isolate of
each phenotype was selected. These isolates (n = 46) were ﬁrst
screened for the epidemiologically most relevant beta-lactamase
genes using the Check-MDRCT-103 tube array according toman-
ufacturers’ protocol (Check-Points, Wageningen, Netherlands).
These targets include: blaCTX−M , blaTEM , blaSHV, blaCMY−1/MOX,
blaACC, blaDHA, blaACT/MIR, blaCMY−2/FOX, blaNDM, blaKPC,
blaVIM, blaIMP, and blaOXA−48. Subsequently, PCR products of
the identiﬁed genes were sent for sequence analysis (Macrogen,
Amsterdam, Netherlands) using primers previously described
(Dierikx et al., 2012b). The online database for ESBL/AmpC genes
was used as a reference (www.lahey.org/studies/; last accessed
10 July 2013) with additional references for blaTEM−52 variants
(GenBank AF126444 and AY883411). Furthermore, sequence
analysis of the chromosomal ampC promoter region was per-
formed, using primers designed by Caroff et al. (1999). The
ampC classiﬁcation was performed as described by Mulvey et al.
(2005).
STATISTICAL ANALYSIS
Conﬁdence intervals for the prevalence estimates were determined
by calculating Exact Binomial Conﬁdence Intervals using SAS v9.2
(SAS Institute Inc., NC, USA).
RESULTS
SAMPLE COLLECTION AND SPECIES IDENTIFICATION
After direct plating, nine healthy dogs (45%) were positive for
cefotaxime reduced susceptible (CTX-RS) E. coli (Table 1). After
selective enrichment, no additional dogs were found positive.
From the diarrheic dogs, 11 animals were positive for CTX-RS
E. coli (55%), of which eight were positive after direct plating and
three more were obtained after selective enrichment. No CTX-RS
Enterobacteriaceae were found in healthy cats. Four cats with diar-
rhea (20%) were positive for CTX-RS E. coli after direct plating
and one animal (5%) was positive for both CTX-RS E. coli and
Proteus mirabilis (25% in total).
ESBL/AmpC CHARACTERIZATION
Molecular analysis showed that within each group of animals
there was a high variety of ESBL/pAmpC genes present, espe-
cially within diarrheic cats (Table 2). In this group four out of
ﬁve animals harbored more than one ESBL/pAmpC gene. The
diarrheic cats were positive for blaCTX−M−1 and −15, blaSHV−12,
blaCMY−2, and a blaTEM−52−StPaul variant. This blaTEM−52−StPaul
variant was identical to the one submitted to GenBank with
number AF126444.
Diarrheic dogs were positive for blaCTX−M−1, −14, blaTEM−35,
and blaCMY−2 genes, of which three animals harbored more
than one type of ESBL/AmpC (Table 2). The strain containing
blaTEM−35, which is an inhibitor resistant TEM (Zhou et al., 1994),
also harbored blaCMY−2. An AmpC phenotype was shown for this
strain by a double disk synergy test.
Healthy dogswere positive for blaCTX−M−1 and blaCMY−2 genes
(Table 2). One healthy dog harbored three ESBL/pAmpC deter-
minants, respectively blaCTX−M−1, blaCMY−2, and an isolate with
reduced susceptibility to cefotaxime in which no resistance gene
was found. Further molecular typing was performed by sequence
analysis of the chromosomal ampC promoter region.
Healthy dogs, diarrheic dogs, and diarrheic cats all harbored
the ampC-type-3 variant (Mulvey et al., 2005). Chromosomal
ampC-types 4, -5, -7, -11, -12, and -18 were also found, however,
Table 1 | Prevalence of cats and dogs carrying ESBL/AmpC producing
Enterobacteriaceae.
Group n screened Prevalence %
(n)
Confidence
interval (95 %)
Dogs healthy 20 45.0 (9) 23.1–68.5
Dogs diarrheic 20 55.0 (11) 31.5–76.9
Dogs total 40 50.0 (20) 33.8–66.2
Cats healthy 20 0.0 (0) 0.0–16.8
Cats diarrheic 20 25.0 (5) 8.7–49.1
Cats total 40 12.5 (5) 4.2–26.8
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Table 2 | Number of animals carrying ESBL/pAmpC genes in Enterobacteriaceae isolated from healthy cats and dogs, and diarrheic cats and
dogs in Netherlands.
Dog Cat
ESBL/AmpC coding gene Healthy Diarrheic Healthy Diarrheic
No. of animals carrying blaCTX−M−1 4 2 – –
blaCTX−M−15 – – – 1
blaCTX−M−14 – 1 – –
blaCTX−M−1 + blaCTX−M−14 – 1 – –
blaCTX−M−1 + blaTEM−52−StPaul – – – 1
blaCTX−M−1 + blaCMY−2 – – – 1
blaCTX−M−1 + blaCMY−2 + ampC type-3 – – – 1f
blaCTX−M−1 + blaCMY−2 + blaTEM−35 – 1a – –
blaCTX−M−1 + blaCMY−2 + unknownb 1 – – –
blaCTX−M−1 + ampC type-3 – 1 – –
blaSHV−12 + blaCMY−2 – – – 1
blaCMY−2 2 2 – –
ampC type-3c 1 1 – –
ampC type-newd 0 1 – –
Unknownb 1 1 – –
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
>1 R genee 1 3 0 4
E. coli 9 11 0 4
E. coli + P. mirabilis 0 0 0 1f
aThis animal carried one E. coli harboring both a blaTEM−35 gene and a blaCMY−2 gene. The blaCTX−M−1 gene and another blaCMY−2 gene were found in separate
E. coli.
b Isolates negative on Check-MDR CT-103 array, and no ampC type-3.
cClassiﬁcation as previously described (Mulvey et al., 2005).
d New ampC variant compared to previously described variants (Mulvey et al., 2005).
eNumber of animals with more than one type of ESBL/pAmpC gene.
fThis animal carried a P. mirabilis harboring a blaCMY−2 gene. All other genes reported in this table were found in E. coli.
based on disk diffusion results, these variants showed ESBL as
well as AmpC phenotypes, depending on the other ESBL/pAmpC
gene present in the same isolate. Therefore the contribution of
these chromosomal mutations to resistance could not be con-
ﬁrmed. Onediarrheic dogharbored anampC type-wt andonenew
ampC variant. The new ampC variant shows close resemblance to
ampC type-2 (Mulvey et al., 2005), with a substitution of cyto-
sine to guanine at position+20. Disk diffusion results showed this
variant had an AmpC phenotype. No other ESBL/AmpC genes
were found in this isolate. Furthermore, two healthy dogs were
negative in the array and harbored either a wild-type ampC or
ampC type-11 gene. Results from the disk diffusion assay were
inconclusive. Because reduced cefotaxime susceptibility caused by
the isolate only harboring an ampC wild-type or type-11 could not
be conﬁrmed phenotypically, these three isolates from the healthy
and diarrheic dog were designated “unknown” (Table 2).
DISCUSSION
In the animals included in this study there is a high level of
intestinal carriage of ESBL/AmpC-producing Enterobacteriaceae
in healthy dogs (45%), and both diarrheic dogs (55%) and cats
(25%). In all animal groups in most fecal samples large num-
bers of reduced susceptible E. coli or P. mirabilis were found
after direct plating on selective MacConkey agar plates. Only few
fecal samples were found positive additionally after inoculation
using themore sensitive selective enrichment and subsequent pure
culturing on selective MacConkey agar. Even though the propor-
tion of ESBL/AmpC producing E. coli/P. mirabilis as part of the
total population of E. coli/P. mirabilis present in the fecal sample
was not determined, this suggests that the bacterial cell count of
ESBL/AmpC producing E. coli/P. mirabilis in these fecal samples
is relatively high.
Due to the small size of the study, the conﬁdence intervals for
the estimated prevalence were relatively large (Table 1). Despite
this fact, the prevalence in the different animal groups, especially
for both healthy and diarrheic dogs, observed in the present study
was relatively high compared to other studies. Costa et al. (2008)
showed in a study on healthy cats (n = 36) and dogs (n = 39)
that two E. coli isolates, both from the same dog, were reduced
susceptible to cefotaxime, indicating a prevalence of 2.6%. The
fact that no selective culturing media were used in that study may
contribute to this large difference. In healthy cats they did not ﬁnd
isolates with reduced susceptibility to cefotaxime. Murphy et al.
(2009) reported that in two regions insouthern Ontario 0% of
both cats (n = 39) and dogs (n = 188) were positive for E. coli with
reduced susceptibility to cefotaxime. In that study, fecal samples
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were also screened using selective media. Gandolﬁ-Decristophoris
et al. (2013) showed that in Switzerland from thefecal swabs that
were taken fromhealthy cats (n= 202) and dogs (n= 174) at nurs-
ing homes and at veterinary clinics, 17% of the examined dogs and
12% of the cats were positive for Enterobacteriaceae with reduced
susceptibility for the 3rd generation cephalosporin cefpodoxime.
In contrast 2.9% of the dogs and 2% of the cats examined were
positive for ESBL genes. This difference in prevalence between cef-
podoxime resistance and presence of ESBL genes may be caused
by the fact that the presence of AmpC type genes was not deter-
mined. As we have shown, blaCMY−2-like genes were present in
more than 10% of all examined isolates. Additionally, we have also
shown that promoter mutations in the chromosomal ampC gene
were present.
Gandolﬁ-Decristophoris et al. (2013) also indicated that
antimicrobial treatment (not further speciﬁed) that was adminis-
tered in the three months prior to the investigation was identiﬁed
as a risk factor for the carriage of ESBL producing Enterobac-
teriaceae. Similar results were shown by Damborg et al. (2011)
in a study in which cefalexin was orally administered to dogs.
This treatment resulted in selection for the presence of blaCMY−2
producing E. coli in the feces. The treatment history of the ani-
mals included in our study is not known. Therefore, any possible
contribution of previous antibiotic usage as described above could
not be established.
In China, a more or less similar prevalence was observed com-
pared to our study (Sun et al., 2010). In their data set 93% of the
samples were fecal samples. From the healthy animals included in
their study, 24.5% (26 out of 109) were positive for ESBL produc-
ing bacteria. From the sick animals 54.5%(73out of 134)were pos-
itive for ESBL producers. This prevalence was based on a double
disk synergy test on isolates obtained from various animal clinics.
The sample size in the present study (20 animals per category)
was relatively small. Therefore extrapolation of the results toward
the general population of cats and dogs in the Netherlands should
be done with great care. The comparisons made to other studies
are regarded appropriate since these studies included sample sets
of more or less comparable size (Murphy et al., 2009; Damborg
et al., 2011; Gandolﬁ-Decristophoris et al., 2013).
The resistance genes reported in this study are similar to those
found in both humans and food-producing animals (EFSA, 2011;
Ewers et al., 2012). The predominant resistance gene reported in
the present study is blaCTX−M−1. The high abundance of this gene
is consistent with studies on isolates from humans and farm ani-
mals in the Netherlands, in which blaCTX−M−1 is either the most
or second most predominant gene (Dierikx et al., 2012a; Voets
et al., 2012; Hordijk et al., 2013; Platteel et al., 2013). However,
more data on plasmids and host bacteria are required to draw
any conclusions on genetic relatedness and possible transmission
to or from either humans or food-producing animals. Further-
more, little is known about persistence of ESBL/AmpC carriage
and about the signiﬁcance of shedding of ESBL/AmpC produc-
ing bacteria by companion animals into their environment. This
requires additional research.
We conclude that despite the estimated prevalence of
ESBL/AmpC producing Enterobacteriaceae especially in both
healthy and diarrheic dogs, but also diarrheic cats is relatively
high. They are certainly a reservoir for the resistance genes.
Whether pets are a source for humans cannot be determined by
this observational study, but this reservoir should certainly be
included in attribution studies for human infections. Further-
more, using selective media to isolate ESBL/AmpC producing
bacteria may reduce the chance to underestimate the prevalence
of these bacteria.
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